Wednesday, November 14, 2018 10:11:03 AM
On November 9, 2018, CTD Holdings, Inc. announced that it had retained Torreya Capital, LLC, as its strategic advisor to support business development.
Then I looked at the Q and that explains it all:
The are down to $216k in shareholder equity (which by my math is around .002 per share book value)
Year over year sales for the 9 mos is down significantly - over 20%
Loss of $2,889,474 for the 9 mos (~$963k per quarter on average)
Bills are stacking up - current assets at 1,710,902 against current liabilities of 1,654,922
Bottom line is the company needs more money and they need outside help to "support business developement". They either need to find investors to put up more millions or a buyout.
Either way -- its looking quite tenuous to me so I'll stay on the sidelines.
As I see it the risk reward possibilities are:
They get funding -- stock price may or may not hold depending on the terms of the deal.
They get a buyout at around $2.00 per share like VTESSE managed (best case scenario).
Neither of the above (worst case scenario) and stock price follows.
________________
LINK TO Q
Recent CYTH News
- Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) • Business Wire • 09/05/2024 01:05:00 PM
- Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law Firm • PR Newswire (US) • 08/26/2024 01:37:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/22/2024 01:37:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 01:36:40 PM
- Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement • Business Wire • 08/22/2024 10:50:00 AM
- Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement • GlobeNewswire Inc. • 08/22/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:50:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:49:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:49:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:49:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:48:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:48:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 05:47:47 PM
- Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:28:23 PM
- Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office • Business Wire • 07/29/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 06:35:02 PM
- Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 • Business Wire • 06/25/2024 01:25:00 PM
- Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 06/14/2024 08:01:00 PM
- Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 • Business Wire • 05/30/2024 01:00:00 PM
- Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/16/2024 12:05:00 PM
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM